Cigna drops coverage of GLP-1 obesity drugs for its own employees
EXCLUSIVE-Cigna drops coverage of GLP-1 obesity drugs for its own employees By Amina Niasse
NEW YORK, June 2 (Reuters) - Health insurer Cigna CI.N will stop covering GLP-1 weight-loss drugs including Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday.
Details of the change in the Cigna Group Medical Plan were announced in an email to employees on June 1.
A Cigna spokesperson confirmed that it was ending the coverage.
“As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss," the spokesperson said. "We remain committed to supporting our employees’ health through a range of weight management programs and resources.”
(Reporting by Amina Niasse; Editing by Caroline Humer and Bill Berkrot)
Recent news on Cigna group
See all newsBrief: Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits And Clinical Support Around Each Person, Improving Affordability And Outcomes
Most Americans support switch to Medicare for all health insurance
Analysis: Vance's fraud crackdown may raise costs for US health insurers, enrollees
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US RESEARCH ROUNDUP-Arxis, Cigna, Vylor